A safety evaluation of guselkumab for the treatment of psoriasis
Sign Up to like & getrecommendations! Published in 2018 at "Expert Opinion on Drug Safety"
DOI: 10.1080/14740338.2018.1488963
Abstract: ABSTRACT Introduction: Guselkumab is a fully human monoclonal IgG1λ antibody for the treatment of plaque psoriasis that inhibits interleukin (IL)-23p19 subunit, reducing the proliferation of type 17 helper T (Th-17) cells and thus production of… read more here.
Keywords: evaluation guselkumab; treatment; safety evaluation; psoriasis ... See more keywords